预约演示

更新于：2026-02-27

Ivermectin

伊维菌素

更新于：2026-02-27

概要

基本信息

简介伊维菌素是一种小分子药物，作为谷氨酸门控氯离子通道的调节剂起作用，这一作用构成了其药理活性的基础。该药物于 1996 年 11 月获得 FDA 批准，其开发可归功于 Merck Sharp & Dohme Corp 的卓越努力。在众多治疗应用中，Ivermectin 用于治疗寄生虫感染，包括疥疮、虱子感染、丝虫象皮病和不同类型的蠕虫病。此外，它已证明在治疗红斑痤疮方面具有疗效，红斑痤疮是一种以炎症为特征的令人不安的皮肤病症。伊维菌素的广谱抗寄生虫作用使其成为旨在控制和消除高流行地区寄生虫感染的大规模药物管理计划的优秀候选者。

药物类型

小分子化药

别名

mdc-STM、CD-5024、K-237

+ [13]

靶点

GluCls

作用方式

调节剂

作用机制

谷氨酸门控氯离子通道调节剂

治疗领域

感染血液及淋巴系统疾病皮肤和肌肉骨骼疾病+ [3]

在研适应症

玫瑰痤疮虱病疥疮+ [10]

非在研适应症

寻常痤疮特应性皮炎头虱

原研机构

Merck Sharp & Dohme Corp.

在研机构

浙江海正药业股份有限公司

Merck Sharp & Dohme Corp.Merck Sharp & Dohme (Australia) Pty Ltd.

+ [9]

非在研机构

Galderma Research & Development SNC

Galderma Holding SATaro Pharmaceuticals U.S.A., Inc.

+ [2]

权益机构

Medicines Patent Pool Foundation

MedinCell SA

Sol-Gel Technologies Ltd.

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1996-11-22),

盘尾丝虫病类圆线虫病

最高研发阶段(中国)批准上市

特殊审评孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C47H72O14

InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N

CAS号70209-81-3

关联

314

项与伊维菌素相关的临床试验

NCT03553615

/ Withdrawn临床2期IIT

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

This pilot trial studies how well a novel oral therapeutic agent performs to treat patients with atopic dermatitis, particularly facial dermatitis.

开始日期2030-12-01

申办/合作机构

Stanford University

NCT06918665

/ Suspended临床1期IIT

HEALTH Trial - Healthy Adult Evaluation of Ivermectin Bioequivalence: Infant Versus Standard Formulation

This is a clinical trial to compare two formulations of the drug ivermectin: the standard 3mg tablet formulation versus a newly developed infant formula preparation. The goal of the trial is to determine if the new formulation functions in the same way, tastes the same and causes no new side effects. The trial will involve 52 participants who will be healthy adult volunteers. The participants will receive both formulations - the order they receive each formulation will be assigned randomly (similar to the toss of a coin).

开始日期2026-05-01

申办/合作机构

Murdoch Childrens Research Institute

[+1]

NCT07396714

/ Not yet recruiting早期临床1期IIT

Evaluation of the Efficacy & Safety of Topical Ivermectin Alone or in Combination With Microneedling as Novel Therapeutic Options for Cutaneous Non-genital Warts Versus Topical Salicylic Acid ؛ Randomized Controlled Clinical Trial.

To compare between the efficacy and safety of topical ivermectin alone, microneedling with topical ivermectin and topical salicylic acid in treatment of cutaneous warts.
topical ivermectin 1% will be applied on warts whole night clinical assessment will be done every 2 weeks
Microneedling will be performed on the lesion using a microneedling pen type device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes until pinpoint bleebing occurs 1 mL of topical ivermectin 1% will be applied on to the wart tissue.
Sessions: Sessions will be performed every 2 weeks until complete cure or for maximum 6 sessions (total 3 month)

开始日期2026-02-01

申办/合作机构

Assiut University

100 项与伊维菌素相关的临床结果

登录后查看更多信息

100 项与伊维菌素相关的转化医学

登录后查看更多信息

100 项与伊维菌素相关的专利（医药）

登录后查看更多信息

7,074

项与伊维菌素相关的文献（医药）

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases

Review

作者: Yang, Xuefan ; Chen, Xiang ; Li, Sitong ; Ruan, Dandan ; Lin, Jiacheng ; Qiu, Xinlan ; Li, Jiaqi ; Ju, Qiang ; Mo, Xiaohui

PURPOSE:

Emerging evidence suggests rosacea as a recognizable adverse event during dupilumab therapy. This study aimed to investigate the potential association between dupilumab and rosacea using pharmacovigilance data and to characterize the clinical features of dupilumab-associated rosacea (DAR) through a review of reported cases.

MATERIALS AND METHODS:

We utilized the FDA Adverse Event Reporting System (FAERS) database (2017-2024) to identify disproportionality signals using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). To contextualize these findings, we performed a focused narrative review of 8 publications comprising 10 DAR cases with extractable individual data.

RESULTS:

A significant disproportionality signal was identified across all four methods (ROR 3.873; PRR 3.872; IC 1.865 with IC025 1.653; EBGM 3.642), with reports predominantly in adults and females. In the case review, a consistent phenotype emerged: papulopustules on persistent centrofacial erythema with frequent burning; facial predominance with occasional extension to neck, scalp, or upper trunk; frequent Demodex detection by scraping, KOH, or in vivo imaging; and occasional granulomatous histology. Onset ranged from approximately 2 weeks to 21 months, including one post-discontinuation case. Most patients improved with rosacea-directed therapy (topical ivermectin or metronidazole; anti-inflammatory-dose doxycycline). However, dechallenge or rechallenge patterns and the need for dose-interval extension, temporary interruption, or switching biologic (e.g., lebrikizumab, upadacitinib) in a subset support a drug-related pattern at the reporting level.

CONCLUSIONS:

DAR represents a distinct clinical entity from dupilumab-associated head and neck dermatitis, which is eczematous and typically responds to antifungals or calcineurin inhibitors. While disproportionality signals indicate association rather than incidence or causality and are subject to reporting bias, clinicians should be aware of this potential adverse event to ensure appropriate management.

2026-06-01·BIOCHEMICAL PHARMACOLOGY

Role of nuclear import proteins in maintaining proteostasis and disease pathogenesis

Review

作者: Nie, Junyu ; Zeng, Xuhui ; Pu, Liping ; Zhao, Xiuling

Nuclear import receptors (NIRs), particularly the importin α/β heterodimer system, function as essential gatekeepers of nucleocytoplasmic trafficking by decoding diverse nuclear localization signals (NLSs) to orchestrate cellular proteostasis. This review delineates the structural basis of NLS recognition and the coordinated mechanisms that facilitate the nuclear import of critical cargoes, including transcription factors, RNA-binding proteins, and DNA repair factors. Beyond their canonical transport role, we emphasize the emerging functions of NIRs as molecular chaperones that suppress aberrant phase separation and their co-translational regulatory roles in ensuring proper protein biogenesis and folding. The collapse of these regulatory functions underpins the pathogenesis of major human diseases. We examine in detail the pathological consequences of nuclear import dysfunction, highlighting its central role in specific neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), oncogenic transformation, and viral pathogenesis. The discussion provides a critical appraisal of emerging therapeutic strategies that target the nuclear import machinery, including small-molecule inhibitors (e.g., importazole, ivermectin), peptide competitors, and advanced delivery platforms. We conclude by providing the associated challenges such as achieving tissue specificity, avoiding off-target effects and the significant opportunities that lie in pharmacologically modulating this fundamental pathway to restore proteostasis and develop disease modifying therapies.

2026-05-01·PREVENTIVE VETERINARY MEDICINE

Knowledge, attitudes, and practices associated with antimicrobial use and antimicrobial resistance among livestock farmers in Botswana

Article

作者: Gatonye, Teresia ; Ntereke, Tlhalefo D ; Rakobe, Gregory T ; Segwagwe, Basiamisi V E ; Lautenbach, Ebbing ; Zankere, Tshiamo ; Parsons, Brianna E ; Ramabu, Solomon S ; Redding, Laurel ; Strysko, Jonathan ; Raboloko, Obuile O ; Lekgowe, Judah O ; Mannathoko, Naledi ; Mokgwathi, Kitso ; Tlhako, Nametso D

INTRODUCTION:

Improper antimicrobial use (AMU) in livestock production is a key driver of antimicrobial resistance (AMR). Despite this, data on AMU among livestock farmers in low- and middle-income countries remains limited. The present study assessed knowledge, attitudes, and practices (KAP) regarding AMU and AMR amongst livestock farmers in Botswana.

METHODS:

A cross-sectional Knowledge, Attitudes, and Practices (KAP) survey was conducted among livestock farmers in southern Botswana, with participant recruitment facilitated by district veterinary service officers. Informed consent was obtained from all participants and surveys were administered by trained research personnel using visual aids to enhance participants recall. Responses to open-ended survey questions assessing knowledge were graded on a standardized 0-5 scale using a rubric while attitude and behavior questions were assessed using binary Yes/No responses.

RESULTS:

A total of 191 farmers participated in the study (71 % male; median age 52 years; median farming experience 14 years). All farmers (100 %,191/191), reported using either antimicrobials or anthelmintics (ivermectin), in the preceding 12 months, accounting for a total of 3322 treatment episodes. Tetracyclines were the most commonly used antimicrobials (53 %,1756/3322), followed by sulphonamides (18 %, 34/191). Cephalosporin, fluoroquinolone and aminoglycoside use was not reported. The farmers, who primarily reared cattle, small ruminants, and chickens, most commonly procured antimicrobials and anthelmintics at agriculture supply stores (91 %,174/191) typically with the guidance of veterinarians or animal health technician (veterinary paraprofessionals), but without a prescription from the veterinarians. Most farmers (66 %,127/191) used antimicrobials for treatment purpose, mainly to treat enteric illness. A total of 34 % of farmers (64/191) reported using antimicrobials for prophylactic purposes. Knowledge about the principles of prudent AMU was generally good although awareness of AMR was limited.

CONCLUSION:

AMU was relatively common among livestock farmers in southern Botswana, primarily for treatment of diseases, with tetracyclines being the most commonly used antimicrobials. Overall, farmers demonstrated generally good knowledge about the principles of prudent AMU. However, comprehensive knowledge of AMR was sub-optimal, reaffirming the need for policy interventions to enhance antimicrobial stewardship in the livestock sector.

200

项与伊维菌素相关的新闻（医药）

2026-02-26

·北京医学感染与传染研究

柳叶刀传染病学 26卷 1-3期（2026年2月26日更新）

THE LANCET Infectious Diseases. Volume 26Number 1 柳叶刀传染病学 26卷 1期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Urgent need for infection prevention and control in prisons 监狱中感染预防和控制的迫切需求 The Lancet Infectious Diseases The Lancet Infectious Diseases Vol 26(1):p1 COMMENT（述评） 2 Now is the time to integrate serology into routine infectious disease surveillance 现在是时候将血清学纳入常规传染病监测了 Simon Cauchemez The Lancet Infectious Diseases Vol 26(1):p2 3 Reassessing sotrovimab's role in COVID-19: insights and implications 重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示 Daniele Focosi,Fabrizio Maggi The Lancet Infectious Diseases Vol 26(1):p3 4 Shaping opportunities for future clinical trials in tuberculosis 为未来结核病临床试验创造机会 Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich The Lancet Infectious Diseases Vol 26(1):p5 5 Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda 乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化 Arjen M Dondorp The Lancet Infectious Diseases Vol 26(1):p6 6 A safe start for PfSPZ Vaccine, but efficacy in children remains elusive PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸 Nicholas Aderinto,Temitomi Jane Oyedele The Lancet Infectious Diseases Vol 26(1):p8 7 Rifasutenizol-based triple therapy for Helicobacter pylori infection 以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染 Jinnan Chen,Hong Lu The Lancet Infectious Diseases Vol 26(1):p9 8 The smallest faith 最渺小的信念 Steven A Pergam The Lancet Infectious Diseases Vol 26(1):p11 9 Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease 新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标 Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson The Lancet Infectious Diseases Vol 26(1):p13 10 Strengthening global preparedness and response to arboviral disease threats: a call to action 加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁 WHO Global Arbovirus Initiative Technical Advisory Group 世界卫生组织全球虫媒病毒倡议技术咨询小组 The Lancet Infectious Diseases Vol 26(1):p15 11 Introducing our cover artist for 2026: Daria Lada 介绍我们2026年的封面艺术家：达里亚·拉达 Marco De Ambrogi The Lancet Infectious Diseases Vol 26(1):p17 Correspondence（读者来信） 12 Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2 新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况 Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann The Lancet Infectious Diseases Vol 26(1):e1 13 Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响 Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens The Lancet Infectious Diseases Vol 26(1):e3 14 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致 Nader Ebrahimi,Amir Ghaemi The Lancet Infectious Diseases Vol 26(1):e6 15 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复 Frank Aarestrup,Marion Koopmans The Lancet Infectious Diseases Vol 26(1):e7 16 Time to tackle vaccine–HLA associations with artificial intelligence 是时候用人工智能解决疫苗-人类白细胞抗原关联问题了 Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington The Lancet Infectious Diseases Vol 26(1):e8 Corrections（更正） 17 Correction to Lancet Infect Dis 2025; published online Oct 29. 《柳叶刀-传染病》2025年更正；在线发表于10月29日 https://doi.org/10.1016/S1473-3099(25)00466-9 The Lancet Infectious Diseases Vol 26(1):e9 18 Correction to Lancet Infect Dis 2025; published online Oct 27. 《柳叶刀-传染病》2025年更正；在线发表于10月27日 https://doi.org/10.1016/S1473-3099(25)00546-8 The Lancet Infectious Diseases Vol 26(1):e9 19 Correction to Lancet Infect Dis 2025; 25: 1084–96 《柳叶刀-传染病》2025年更正；25卷：1084-1096页 The Lancet Infectious Diseases Vol 26(1):e9 20 Correction to Lancet Infect Dis 2025; published online Nov 10. 《柳叶刀-传染病》2025年更正；在线发表于11月10日 https://doi.org/10.1016/S1473-3099(25)00550-X The Lancet Infectious Diseases Vol 26(1):e9 Newsdesk（新闻台） 21 Highlights of IDWeek 2025 2025年IDWeek亮点 Phoebe Hall The Lancet Infectious Diseases Vol 26(1):e10 22 WHO publishes update on global antibiotic resistance 世界卫生组织发布全球抗生素耐药性最新情况 Timothy Jesudason The Lancet Infectious Diseases Vol 26(1):e11 23 European Commission to fund new medicines for dengue 欧盟委员会资助登革热新药研发 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):e12 24 Second report from the UK Covid-19 Inquiry 英国新冠肺炎调查第二次报告 Talha Burki The Lancet Infectious Diseases Vol 26(1):e13 25 Infectious disease surveillance update 传染病监测最新情况 Cahal McQuillan The Lancet Infectious Diseases Vol 26(1):e14 26 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases Vol 26(1):e15 Obituary（讣告） 27 Jean Louis Abdourahim Ndiaye 让·路易斯·阿卜杜拉希姆·恩迪亚耶 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):p19 Profile（人物介绍） 28 Fortunate Machingura—tackling climate change and disease 福图纳特·马辛古拉——应对气候变化与疾病 Tony Kirby The Lancet Infectious Diseases Vol 26(1):p20 Media Watch（媒体观察） Book（书籍） 29 The social and political drivers behind pandemics 大流行背后的社会和政治驱动因素 Emma Louise Fabiani The Lancet Infectious Diseases Vol 26(1):p21 Articles（论著） 30 Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study 新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究 Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek The Lancet Infectious Diseases Vol 26(1):p22 31 Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验 RECOVERY Collaborative Group RECOVERY协作组 The Lancet Infectious Diseases Vol 26(1):p34 32 A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial 含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验 John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team The Lancet Infectious Diseases Vol 26(1):p46 33 Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories 2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析 Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar The Lancet Infectious Diseases Vol 26(1):p55 34 Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial 乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验 Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka The Lancet Infectious Diseases Vol 26(1):p67 35 Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial 加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验 Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller The Lancet Infectious Diseases Vol 26(1):p79 36 Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究 Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda The Lancet Infectious Diseases Vol 26(1):p91 37 Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial 以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验 Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group The Lancet Infectious Diseases Vol 26(1):p101 Series（专题研讨会） 38 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Innovation in active and passive immunisation of people who are immunocompromised: a call to action 免疫功能低下人群主动和被动免疫接种的创新：行动呼吁 Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa The Lancet Infectious Diseases Vol 26(1):e16 39 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship 应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理 Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo The Lancet Infectious Diseases Vol 26(1):e30 Review（综述） 40 Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project 揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述 Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro The Lancet Infectious Diseases Vol 26(1):e49 Personal View（个人观点） 41 Azithromycin mass drug administration: balancing survival benefits and risks in children 阿奇霉素大规模药物给药：平衡儿童生存益处与风险 Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro The Lancet Infectious Diseases Vol 26(1):e62 Clinical Picture（临床影像） 42 Unexpected finding in a 17-year-old female undergoing screening colonoscopy 17岁女性接受筛查结肠镜检查时的意外发现 Ziheng Calvin Xu,Ethan Tan,Mayur Garg The Lancet Infectious Diseases Vol 26(1):e75 THE LANCET Infectious Diseases. Volume 26Number 2 柳叶刀传染病学 26卷 2期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Call for letters 征稿启事 The Lancet Infectious Diseases The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111 Comment（述评） 2 Long COVID is here to stay—even in children 长期新冠症状将持续存在——即使在儿童中亦是如此 Danilo Buonsenso The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112 3 Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment 利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用 Ming Hong Choi,Ivan Fan Ngai Hung The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113 4 A new monoclonal in the arMAMentarium against malaria 抗疟“武器库”中的新型单克隆抗体 Freia-Raphaella Lorenz,Matthew B B McCall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115 5 Household transmission of mpox in Africa: limited in adults but more prevalent in children 非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍 Oriol Mitjà,Michael Marks The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117 6 The lasting lessons of mpox: infection, vaccination, and immune memory 猴痘带来的持久教训：感染、疫苗接种和免疫记忆 Raianna Fantin,Camila H Coelho The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118 7 Xpert-Ultra for diagnosing asymptomatic tuberculosis Xpert-Ultra用于诊断无症状结核病 Xia Yu,Hairong Huang The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120 8 The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action 基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动 David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122 Correspondence（读者来信） 9 Spillover in dengue trials 登革热试验中的溢出效应 Thomas A Smith,Samuel I Watson The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77 10 Spillover in dengue trials – Author's reply 登革热试验中的溢出效应——作者回复 Fernando Abad-Franch The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78 11 Updating the traditional voriconazole trough concentration range 传统的伏立康唑谷浓度范围更新 Rongqiang Liao,Xiaoyuan Zheng The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79 12 Updating the traditional voriconazole trough concentration range – Authors' reply 传统的伏立康唑谷浓度范围更新——作者回复 Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80 13 Clinical course and neurological profile of Kyasanur Forest disease 基萨努尔森林病的临床病程和神经特征 Nitin Gupta,Tirlangi Praveen Kumar The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82 Corrections（更正） 14 Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7 对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 15 Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4 对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 Newsdesk（新闻台） 16 Promising early data for sorfequiline 索氟维林早期数据令人鼓舞 Ed Holt The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84 17 Highlights from ASTMH 2025 2025年美国热带医学与卫生学会年会亮点 Marco De Ambrogi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85 18 Brazil approves domestic single-shot dengue vaccine 巴西批准国产单剂登革热疫苗 Marcia Triunfol The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86 19 CDC cuts to childhood vaccine recommendations 美国疾控中心削减儿童疫苗接种建议 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87 20 WHO launches unified plan for coronaviruses 世界卫生组织启动冠状病毒统一计划 Talha Burki The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88 21 Infectious disease surveillance update 传染病监测更新 Cahal McQuillan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89 22 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90 Obituary（讣告） 23 Walter Dowdle 沃尔特·道德尔 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124 Profile（人物简介） 24 Katie Anders—improving global dengue control 凯蒂·安德斯——改善全球登革热防控 Tony Kirby The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125 Media Watch（媒体观察） Film（电影） 25 Eliminating Guinea worm 根除麦地那龙线虫 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126 Articles（论著） 26 Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study 奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127 27 Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial 口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验 William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139 28 Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial 头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验 David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148 29 Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验 single-blind, randomised, controlled, dose-ranging, phase 2 trial Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160 30 Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial 人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验 Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170 31 Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study 布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究 Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182 32 Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study 比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究 Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190 33 Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study 乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究 Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203 Review（综述） 34 Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge 侵袭性A组链球菌感染：从2022-23年激增中吸取的教训 Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91 35 A clinical practice guideline for tuberculous meningitis 结核性脑膜炎临床实践指南 Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96 36 Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults 缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症 Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112 Personal View（个人观点） 37 A transformation in cholera surveillance 霍乱监测的变革 Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124 Clinical Picture（临床图像） 38 Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing 尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展 Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130 THE LANCET Infectious Diseases. Volume 26Number 3 柳叶刀传染病学 26卷 3期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL（社论） 1 Promises and challenges of AI in infectious diseases 人工智能在传染病领域的承诺与挑战 The Lancet Infectious Diseases The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213 COMMENT（述评） 2 More real-world evidence for RSV vaccines in the global community 全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据 Kristina L Bajema,Wesley H Self The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214 3 Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet 猴痘快速诊断抗原检测及分散检测的必要性——尚待完善 Daniel Mukadi-Bamuleka,Kevin K Ariën The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215 4 Solving the data bottleneck for artificial intelligence in infectious diseases 解决传染病人工智能领域的数据瓶颈问题 Cesar de la Fuente-Nunez The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217 5 Artificial intelligence and One Health: potential for spillover prediction? 人工智能与“同一健康”理念：能否预测病原体外溢？ Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219 6 Artificial intelligence in the development of vaccines for infectious diseases 人工智能在传染病疫苗研发中的应用 Steve Black,Shabir A Madhi,Rino Rappuoli The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221 7 Peer review at The Lancet Infectious Diseases in 2025 2025年《柳叶刀-传染病学》期刊专家评审 Ursula Hofer The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223 8 Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025 感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家 The Lancet Infectious Diseases Editors The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132 CORRESPONDENCE（读者来信） 9 Methodological considerations in the attribution of long COVID to first or second infection 首次或二次感染导致长期新冠症状的方法学考量 Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139 10 Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply 首次或二次感染导致长期新冠症状的方法学考量——作者回复 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141 11 Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答 Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142 12 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者 Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144 13 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复 David L Paterson,Abdullah T Aslan,Patrick N A Harris The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145 CORRECTIONS（更正） 14 Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0 《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0 The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 15 Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X 《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 NEWSDESK（新闻台） 16 Rabies an increasing threat in Ukraine 乌克兰狂犬病威胁日益加剧 Ed Holt The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147 17 People needing trachoma interventions at record low 需要沙眼干预措施的人数创历史新低 Timothy Jesudason The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148 18 Uneven STI response in EU/EEA countries 欧盟/欧洲经济区国家性传播感染应对措施不均衡 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149 19 Controversial HBV vaccine trial in Guinea-Bissau halted 几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停 Talha Burki The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150 20 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151 OBITUARY（讣告） 21 Ivan Hirsch 伊万·赫希 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224 PROFILE（人物介绍） 22 Reem Abu Shomar— championing water safety in Gaza 里姆·阿布·舒马尔——加沙地带水安全倡导者 Tony Kirby The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225 MEDIA WATCH（媒体观察） Book（书籍） 23 A prescription for public health literacy 提升公众健康素养的良方 Vijay Shankar Balakrishnan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226 Book（书籍） 24 Imagining the inevitable 想象不可避免之事 Cahal McQuillan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227 Film（电影） 25 Women's autonomy, safe sex and HIV prevention 女性自主权、安全性行为与艾滋病预防 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228 ARTICLES（论著） 26 Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study 英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究 Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229 27 Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial 印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验 Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239 28 Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial 血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析 Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250 29 Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study 刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究 Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260 30 Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis 伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析 Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270 31 Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析 GBD 2023 Chagas Disease and RAISE Study Collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284 32 Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial 乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验 Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302 33 Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial 美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验 Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314 SERIES（研讨会） Artificial Intelligence and Infectious Diseases 人工智能与传染病 34 Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice 人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架 Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152 35 Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives 人工智能与传染病诊断：现状与未来展望 Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168 36 Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery 人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现 Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181 REVIEW（综述） 37 Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia 血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议 Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193 CLINICAL PICTURE（临床图像） 38 Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection 人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染 Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B Spiller,Baharak Afshar The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207

疫苗信使RNA临床1期临床研究

2026-02-23

·BioSpace

Kennedy Ally Departs CDC Amid Leadership Shake-Up

iStock, Anton Vierietin Ralph Abraham, a vocal vaccine skeptic who served at the agency for just three months, has stepped down due to “unforeseen family obligations,” according to the CDC. Another domino has fallen at the CDC, with Principal Deputy Director Ralph Abraham stepping down effective immediately, the public health organization announced Monday morning. Last week, acting CDC Director Jim O’Neill left his position. That left Abraham as the most senior leader at the agency until National Institutes of Health Director Jay Bhattacharya assumed leadership of the CDC on an acting basis on Friday. Abraham, a physician, former Congressman and recent surgeon general of Louisiana, was sworn in by Health and Human Services Secretary Robert F. Kennedy Jr. on December 15, 2025 . Now, just a few months later, he has stepped down due to “unforeseen family obligations,” according to the CDC’s brief statement announcing the departure. “Dr. Abraham led with clarity and discipline, advancing the CDC’s mission to protect the health and safety of the American people,” the statement said. “He worked directly with career staff and public health partners to strengthen national preparedness and improve the country’s emergency response efforts.” Abraham is a longtime ally of President Donald Trump and of Kennedy, according to reporting from NPR . Abraham is also a noted skeptic of vaccines and campaigned against COVID-19 shots during the pandemic. In his role as surgeon general of Louisiana, he banned all vaccine promotion campaigns, including COVID, flu and mpox. Abraham also encouraged the use of ivermectin as a treatment for COVID, an idea that was thoroughly debunked using clinical evidence.

高管变更疫苗

2026-02-22

·道道之道

【本周医刊】2026年第8周医学期刊更新

2026年第8周（2026.02.15-2026.02.21）重要医学期刊论著更新如下： 1.综合期刊 LANCET 题目：Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial 翻译：替奈普酶对比标准药物治疗 24 小时内基底动脉闭塞（TRACE‑5）：一项多中心、前瞻性、随机、开放标签、终点盲法、优效性Ⅲ期临床试验题目：Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial 翻译：重组凝血因子Ⅶa对比安慰剂用于症状发作2 小时内自发性脑出血（FASTEST）：一项多中心、双盲、随机、安慰剂对照Ⅲ期临床试验题目：Cumulative incidence of advanced breast cancer in women aged 40–49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis 翻译：日本附加超声筛查抗癌随机试验（J‑START）中40～49岁女性晚期乳腺癌累积发病率：一项预设亚组分析题目：Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial 翻译：艾菲莫肽 α（BOS‑580）每月一次治疗F2/F3 纤维化代谢相关脂肪性肝炎：一项24 周、随机、双盲、安慰剂对照Ⅱ期临床试验结果 NEW ENGLAND JOURNAL OF MEDICINE 题目：Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 翻译：泰莱斯塔单抗联合达雷妥尤单抗治疗复发或难治性多发性骨髓瘤题目：Hematopoietic Stem-Cell Gene Therapy for Cystinosis 翻译：胱氨酸病的造血干细胞基因治疗题目：An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1 翻译：用于 1 型强直性肌营养不良的抗体- 寡核苷酸偶联物题目：Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years 翻译：低危患者经导管或外科主动脉瓣置换术后7 年结局 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 题目：Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial 翻译：期待治疗对比药物治疗早产儿动脉导管未闭：PDA随机临床试验题目：Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial 翻译：冻存血小板对比液态保存血小板治疗外科出血：CLIP‑II随机非劣效性临床试验题目：Prenatal Exposure to Acid-Suppressive Medications and Risk of Neuropsychiatric Disorders in Children 翻译：产前暴露于抑酸药物与儿童神经精神疾病发病风险的关系 NATURE MEDICINE 题目：Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial 翻译：结肠镜联合粪便免疫化学检测对比常规方案用于结直肠癌诊断性筛查：SCREESCO随机对照试验题目：Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks 翻译：血浆 p-tau217 时钟预测症状性阿尔茨海默病发病题目：Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases 翻译：双特异性 T 细胞衔接器用于治疗难治性自身免疫性结缔组织病题目：Deciphering the etiology of the 2024 outbreak of undiagnosed febrile illness in Panzi, Democratic Republic of the Congo 翻译：解析刚果民主共和国潘齐市 2024 年不明原因发热疫情的病因题目：Effects of a comprehensive antibiotic stewardship program on antibiotic prescribing for acute respiratory infections in rural facilities: a cluster randomized trial 翻译：综合性抗生素管理项目对基层医疗机构急性呼吸道感染抗生素处方的影响：一项整群随机试验题目：A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial 翻译：短效致幻剂干预治疗重度抑郁症：一项Ⅱa期随机安慰剂对照试验题目：A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders 翻译：用于路易体病诊断的定量多巴脱羧酶生物标志物 BMJ-BRITISH MEDICAL JOURNAL 题目：Menopausal hormone therapy and long term mortality 翻译：绝经激素治疗与长期死亡率题目：Vitamin D supplementation before in vitro fertilisation in women with polycystic ovary syndrome 翻译：多囊卵巢综合征女性体外受精前的维生素D 补充 INNOVATION（本周无更新） LANCET DIGITAL HEALTH（本周无更新） NPJ DIGITAL MEDICINE 题目：A large-scale benchmark for evaluating large language models on medical question answering in Romanian 翻译：面向罗马尼亚语医学问答的大语言模型大规模基准评测题目：Artificial intelligence–enhanced microsurgical training: a systematic review 翻译：人工智能增强的显微外科培训：一项系统评价题目：Defining operational safety in clinical artificial intelligence systems 翻译：临床人工智能系统中操作性安全性的定义题目：CancerLLM: a large language model in cancer domain 翻译：CancerLLM：一款肿瘤领域专用大语言模型题目：Robust and interpretable unit level causal inference in neural networks for pediatric myopia 翻译：基于神经网络的儿童近视个体水平稳健可解释因果推断题目：Large language models in systematic review and meta-analysis of surgical treatments for vaginal vault prolapse 翻译：大语言模型在阴道穹隆脱垂手术治疗系统评价与Meta 分析中的应用题目：Hierarchical deep learning pipeline for robust cervical parameter measurement in radiographs with C7 obscuration 翻译：针对 C7 节段遮挡X 光片的稳健性颈椎参数测量分层深度学习流程题目：Benchmarking large language model-based agent systems for clinical decision tasks 翻译：面向临床决策任务的大语言模型智能体系统基准测试题目：Computer vision applications in vascular surgery: a systematic review and critical appraisal 翻译：计算机视觉在血管外科中的应用：一项系统评价与批判性评价题目：Empowering genetic discoveries and cardiovascular risk assessment by predicting electrocardiograms from genotype 翻译：通过基因型预测心电图以助力遗传学发现与心血管风险评估题目：BRIDGE pilot study: a bilateral regulatory investigation of data governance and exchange 翻译：BRIDGE 试点研究：一项关于数据治理与数据交换的双边监管调查题目：Artificial intelligence-based incident analysis and learning system to enhance patient safety and improve treatment quality 翻译：基于人工智能的不良事件分析与学习系统：提升患者安全与治疗质量题目：Health economic simulation modeling of an AI-enabled clinical decision support system for coronary revascularization 翻译：面向冠脉血运重建的人工智能临床决策支持系统卫生经济学模拟建模题目：A deep learning model integrating structured data and clinical text for predicting atrial fibrillation recurrence 翻译：整合结构化数据与临床文本的深度学习模型预测心房颤动复发题目：Risk Prediction of Chronic Kidney Disease Progression in Type 2 Diabetes Mellitus Across Diverse Populations 翻译：不同人群中 2 型糖尿病患者慢性肾脏病进展的风险预测题目：Randomized-controlled trial of skills-based vr vs. distraction vr vs. sham VR for chronic low back pain 翻译：基于技能的虚拟现实、分散注意力虚拟现实与假虚拟现实治疗慢性下腰痛的随机对照试验题目：Bridging radiology and pathology: domain-generalized cross-modal learning for clinical 翻译：桥接放射学与病理学：面向临床的域泛化跨模态学习 2.肿瘤学 CA-A CANCER JOURNAL FOR CLINICIANS（本周无更新） ANNALS OF ONCOLOGY 题目：Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study 翻译：卡博替尼联合纳武利尤单抗 + 伊匹木单抗治疗初治晚期肾细胞癌：Ⅲ期COSMIC-313 研究最终结果与生物标志物分析题目：Learning the Forest Before the Trees: Artificial Intelligence and Thymic Tumor Pathology 翻译：先见森林后见树木：人工智能与胸腺肿瘤病理学题目：ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours 翻译：ESMO 系统性治疗线数适配方案（EnLiST）：实体瘤治疗线数定义标准化共识框架题目：Doubting T(h)OMAS: Has the era of precision oncology arrived in uterine leiomyosarcoma? 翻译：质疑 T (h) OMAS：精准肿瘤学时代是否已降临子宫平滑肌肉瘤？题目：PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM) 翻译：德国国家肺癌基因组医学网络（nNGM）：转移性肺癌长期应答者的PET/CT 指导下免疫检查点阻断治疗管理及治疗后多组学分析 JOURNAL OF CLINICAL ONCOLOGY 题目：Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial 翻译：肝动脉灌注泵化疗治疗不可切除肝内胆管癌——PUMP‑2 试验题目：BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 翻译：BRUIN CLL‑313：吡托布鲁替尼对比苯达莫司汀联合利妥昔单抗治疗初治慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤的随机Ⅲ期试验题目：Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 翻译：吡托布鲁替尼对比伊布替尼治疗初治及复发/ 难治性慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤题目：Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study 翻译：淋巴结阳性、激素受体阳性绝经前乳腺癌患者接受5 年促黄体生成素释放激素激动剂辅助治疗后的延长内分泌治疗：一项队列研究题目：NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal 翻译：NCI9673（B部分）：纳武利尤单抗联合或不联合伊匹木单抗治疗难治性转移性肛管鳞状细胞癌的ETCTN 随机Ⅱ期试验 LANCET ONCOLOGY（本周无更新） JOURNAL OF THORACIC ONCOLOGY（本周无更新） JAMA ONCOLOGY 题目：Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial 翻译：循环肿瘤 DNA 在接受塞来昔布治疗的Ⅲ期结肠癌中的预测价值：CALGB（Alliance）/SWOG 80702 Ⅲ期随机临床试验的事后分析题目：Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial 翻译：绝经前与绝经后女性的认知功能损伤及化疗内分泌治疗对比内分泌治疗：RxPONDER随机临床试验的二次分析题目：Enhancement of Patient-Centered Lung Cancer Screening: The MyLungHealth Randomized Clinical Trial 翻译：以患者为中心的肺癌筛查优化：MyLungHealth 随机临床试验题目：Quadrivalent Human Papillomavirus Vaccine and High-Grade Vulvovaginal Lesions 翻译：四价人乳头瘤病毒疫苗与高级别外阴阴道病变题目：Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy 翻译：接受全身治疗的癌症患者基线疲劳程度与严重毒性反应 CANCER RESEARCH 题目：EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression 翻译：抑制 EZH2 可增加前列腺癌谱系变异演化多样性，但无法有效抑制疾病进展题目：The Aging Microenvironment Is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer 翻译：衰老微环境是胰腺癌免疫排斥与转移命运的决定因素题目：Mitochondrial Transfer Rescues Respiration to Support De Novo Pyrimidine Biosynthesis and Tumor Progression 翻译：线粒体转移可恢复呼吸作用，支持从头嘧啶合成与肿瘤进展题目：Dissection of Gαs and Hedgehog Signaling Cross-talk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors 翻译：解析 Gαs与Hedgehog 信号通路交互作用，为靶向Hedgehog 依赖性肿瘤提供治疗策略题目：Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation 翻译：肿瘤发生阶段，BMP2/4–ACVR1信号介导的促肿瘤巨噬细胞极化构建免疫抑制微环境题目：Tetraspanin 13 Enhances Immune Evasion in Breast Cancer by Promoting MHC-I Degradation 翻译：四次跨膜蛋白 13 通过促进MHC‑I 降解增强乳腺癌免疫逃逸题目：Cancer-Associated Fibroblasts Promote Imatinib Resistance in Gastrointestinal Stromal Tumors through PGK1-Mediated Metabolic Reprogramming 翻译：癌相关成纤维细胞通过 PGK1 介导的代谢重编程促进胃肠道间质瘤对伊马替尼耐药题目：Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma 翻译：p300 催化抑制可优先靶向多发性骨髓瘤中IRF4 致癌活性与肿瘤生长题目：CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer 翻译：CRISPR‑Cas9 筛选揭示胰腺癌对KRAS 抑制的耐药机制题目：An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation 翻译：一类分泌细胞外基质的癌相关成纤维细胞亚群通过SRC 激活与G0S2 上调驱动乳腺癌化疗耐药题目：Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer 翻译：动态且持续的从头 L1 逆转录转座促进卵巢癌基因组可塑性与患者内异质性 CLINICAL CANCER RESEARCH 题目：Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial 翻译：哌柏西利、曲妥珠单抗联合内分泌治疗既往接受过治疗的HER2 阳性、PAM50腔面型晚期乳腺癌：SOLTI‑1303 PATRICIA 随机Ⅱ期临床试验题目：FDG-PET–Based Selective Deescalation of Chemoradiation in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial 翻译：基于 FDG‑PET 选择性降阶梯放化疗治疗人乳头瘤病毒相关口咽鳞状细胞癌：一项多中心Ⅱ期临床试验题目：T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma 翻译：度伐利尤单抗单药或联合曲美木单抗 / 贝伐珠单抗治疗不可切除肝细胞癌的T 细胞受体与免疫基因表达药效学研究题目：HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study 翻译：PD‑1/PD‑L1 抗体联合预防性抗病毒药物治疗肝细胞癌患者的乙肝病毒再激活：一项前瞻性观察性研究题目：Anti–LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial 翻译：抗 LAG‑3 抗体LBL‑007 联合替雷利珠单抗与化疗作为晚期鼻咽癌一线治疗：一项多中心Ⅱ期临床试验题目：Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma 翻译：GOG281/LOGS 研究的分子谱与肿瘤生物标志物分析：曲美替尼治疗复发性/ 持续性低级别浆液性卵巢癌的阳性晚期试验题目：Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma 翻译：血浆 ctDNA 早期动力学与外周T 细胞受体库预测头颈部鳞状细胞癌PD‑1 抑制剂治疗疗效题目：Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer 翻译：可切除非小细胞肺癌中，微小残留病可在病理缓解之外进一步提升预后分层效能题目：Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor (PIGR) 翻译：联合氨基肽酶 N（ANPEP）与多聚免疫球蛋白受体（PIGR）优化胰腺导管腺癌早期检测血浆生物标志物panel 题目：Germline Pathogenic Variant Prediction Model for Tumor-Only Sequencing Based on Japanese Clinicogenomic Database 翻译：基于日本临床基因组数据库的仅肿瘤测序胚系致病变异预测模型题目：Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity 翻译：TNFR2 上调先于耗竭T 细胞TOX 表达，并抑制抗肿瘤与抗病毒免疫题目：Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer 翻译：微卫星不稳定性与肿瘤突变负荷在预测转移性去势抵抗性前列腺癌免疫检查点抑制剂疗效中的附加临床价值题目：A Generative Foundation Model for Scalable Cytology Image Synthesis in AI-Powered Diagnostics 翻译：用于 AI 辅助诊断中可规模化细胞学图像合成的生成式基础模型 JOURNAL OF THE NATIONAL CANCER CENTER 题目：Clinicopathologic, genetic and immune cell infiltration analysis of colorectal signet ring cell carcinoma with comparison to conventional adenocarcinoma 翻译：结直肠印戒细胞癌的临床病理、遗传学及免疫细胞浸润分析——并与常规腺癌对比 JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE（本周无更新） 3.内分泌学与代谢 LANCET DIABETES & ENDOCRINOLOGY 题目：Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study 翻译：手术治疗对比保守治疗对双侧肾上腺肿瘤合并皮质醇增多患者心血管结局的影响：一项国际回顾性队列研究题目：3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial 翻译：罗莫佐单抗治疗绝经后骨质疏松症 3 个月对比12 个月（LIDA）：一项开放标签、非劣效性随机对照试验题目：Temporal changes and genetic susceptibility to type 2 diabetes (1984–2019; HUNT): a longitudinal, population-based study 翻译：2 型糖尿病的时间变化趋势与遗传易感性（1984–2019；HUNT研究）：一项基于人群的纵向研究题目：Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial 翻译：英克西兰治疗杂合子家族性高胆固醇血症青少年的有效性与安全性（ORION‑16）：一项两阶段、多中心随机临床试验 DIABETES CARE 题目：The Effect of Midpregnancy Screening for Gestational Diabetes Mellitus on Pregnancy Outcomes: The TESGO Randomized Controlled Trial 翻译：妊娠中期妊娠期糖尿病筛查对妊娠结局的影响：TESGO随机对照试验题目：Generalizability of Progression Risk in the TN-10 Trial to a European Population With or Without a First-Degree Relative With Type 1 Diabetes 翻译：TN-10 研究中进展风险在有无1 型糖尿病一级亲属的欧洲人群中的外推性题目：Safety and Feasibility of a Fully Automated Insulin Delivery System: FCL@Home, a Multicenter Randomized Clinical Trial in Individuals With Type 1 Diabetes 翻译：全自动胰岛素输注系统的安全性与可行性：FCL@Home——一项针对1 型糖尿病患者的多中心随机临床试验题目：Impact of Maternal Diabetes in Pregnancy on Newborn IgG Antibody Repertoire and Infection Risk in the First 6 Months of Life 翻译：孕期母体糖尿病对新生儿 IgG 抗体谱及出生后6 个月内感染风险的影响题目：MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses 翻译：无用户主动推注期间 MiniMed 780G 高级混合闭环系统的使用情况题目：Metabolic Factors Modulating the Connection Between Diabetes and Pulmonary Alterations 翻译：调控糖尿病与肺部改变之间关联的代谢因素题目：Interoceptive Awareness Moderates the Relationship Between Hypoglycemia Exposure and Symptom Recognition in Adults With Type 1 Diabetes 翻译：内感受感知调节 1 型糖尿病成人低血糖暴露与症状识别之间的关系题目：Associations of Moderate-to-Vigorous Physical Activity Timing With Type 2 Diabetes Incidence in UK Biobank and Prevalent Glycemic Measures in NHANES 翻译：英国生物银行中中高强度体力活动时间与2 型糖尿病发病风险的关联及NHANES 中血糖相关指标的横断面分析题目：Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease 翻译：可溶性尿激酶型纤溶酶原激活物受体（suPAR）介导糖尿病对冠心病不良结局的影响题目：Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies 翻译：痛风合并 2 型糖尿病患者启动钠- 葡萄糖协同转运蛋白2 抑制剂后痛风相关药物使用：基于人群的目标试验模拟研究题目：A Comparison of Diet and Exercise During Pregnancy in Women With and Without Type 1 Diabetes Followed in the Environmental Determinants of Islet Autoimmunity (ENDIA) Study 翻译：胰岛自身免疫环境决定因素（ENDIA）研究中1 型糖尿病与非1 型糖尿病孕妇孕期饮食与运动的比较题目：Chronic Kidney Disease and Risk of Diabetic Ketoacidosis in Type 1 Diabetes 翻译：慢性肾脏病与 1 型糖尿病糖尿病酮症酸中毒风险的关系题目：Assessing Time Below Range as a Predictor of Severe Hypoglycemia: Insights From Six Clinical Trials 翻译：评估血糖低于范围时间作为严重低血糖的预测因子：六项临床试验的启示题目：Global, Regional, and National Estimates of Undiagnosed Diabetes in Adults: Findings From the 2025 IDF Diabetes Atlas 翻译：全球、区域及国家层面成人未确诊糖尿病估计：2025年IDF 糖尿病图谱结果题目：Sex Hormones and Cardiovascular Risk in Type 2 Diabetes: Cohort Study of the Look AHEAD Trial 翻译：2 型糖尿病中性激素与心血管风险：Look AHEAD 试验的队列研究题目：Rapid Postpartum Progression to Diabetes Following Early Antenatal Prediabetes: Evidence From a Multiethnic New Zealand Cohort 翻译：孕期早期 prediabetes 后产后快速进展为糖尿病：新西兰多种族队列研究证据 4.心血管病学 CIRCULATION 题目：Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women 翻译：妊娠期高血压疾病与美国多种族年轻女性早发性心血管疾病的关系题目：Polycystic Ovarian Syndrome and the Long-Term Risk of Arrhythmias 翻译：多囊卵巢综合征与心律失常长期发病风险题目：Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study 翻译：孕期停用他汀类药物与母体心血管健康及分娩结局的关联：一项全国性队列研究题目：Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension 翻译：乳腺癌揭示潜在的BMPR2相关肺动脉高压易感性 EUROPEAN HEART JOURNAL 题目：Catheter ablation in congenital heart diseases: a French nationwide study 翻译：先天性心脏病的导管消融术：一项法国全国性研究题目：Arrhythmias in congenitally corrected transposition of the great arteries: an international study 翻译：先天性矫正型大动脉转位中的心律失常：一项国际研究题目：Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry 翻译：单心室循环患儿接受 Fontan 手术的早期结局：EuroFontan注册登记研究题目：Adults with Fontan circulation: prognostic value of exercise pulmonary vascular resistance index 翻译：Fontan 循环成人患者：运动肺血管阻力指数的预后价值 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 题目：Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients 翻译：绝经状态与乳腺癌患者多西他赛诱导的血管功能障碍相关题目：Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial 翻译：DanGer 休克研究：梗死相关性心源性休克中微型轴流泵的使用及结局存在性别差异 5.胃肠肝病学 LANCET GASTROENTEROLOGY & HEPATOLOGY（本周无更新） JOURNAL OF HEPATOLOGY 题目：Genetic and non-genetic drivers of histological progression and regression in MASLD 翻译：MASLD 组织学进展与逆转的遗传及非遗传驱动因素题目：HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses 翻译：HBx 诱导的HSPB1 通过调控HBV cccDNA 与肝脏免疫反应成为潜在治疗靶点题目：Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program 翻译：国际同情用药项目中 REP 2139-Mg 治疗HDV 相关晚期肝病的安全性与有效性题目：Refining the Baveno VII criteria for clinically significant portal hypertension: An individual patient data meta-analysis 翻译：优化具有临床意义门静脉高压的 Baveno VII 标准：一项个体患者数据荟萃分析题目：Setd4-expressing cells drive regenerative recovery in chronic liver injury 翻译：表达 Setd4 的细胞介导慢性肝损伤的再生修复题目：Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma 翻译：处理生存曲线间非比例风险的策略——来自肝细胞癌Ⅲ期试验的启示题目：HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort 翻译：HEDS 队列中HES V2.0 与GALAD、ASAP的对比验证及性能评估题目：Genetically engineered pig-to-human liver xenotransplantation 翻译：基因工程猪 - 人肝脏异种移植题目：PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy 翻译：PARG 抑制通过Hippo 通路阻断胆管癌进展并增强化疗与免疫治疗应答题目：Transcriptomic and epigenetic mechanisms controlling cholangiocyte transdifferentiation into hepatocytes 翻译：调控胆管细胞转分化为肝细胞的转录组与表观遗传机制 GUT 题目：MTFP1 drives pancreatic cancer liver metastatic colonisation by regulating mitochondrial metabolism reprogramming 翻译：MTFP1 通过调控线粒体代谢重编程驱动胰腺癌肝转移定植题目：Oleic acid promotes lung injury in hypertriglyceridaemia-associated acute pancreatitis via the PIEZO1/NR4A1/CPT1A axis impairing endothelial fatty acid oxidation 翻译：油酸通过 PIEZO1/NR4A1/CPT1A 轴损伤内皮细胞脂肪酸氧化，加重高甘油三酯血症相关性急性胰腺炎的肺损伤题目：E-cadherin loss in Cd44-positive gastric cells initiates diffuse gastric cancer in a murine model 翻译：小鼠模型中 Cd44 阳性胃上皮细胞E‑钙黏蛋白缺失可启动弥漫型胃癌发生题目：Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy 翻译：患者配对 HER2 阳性胃癌的空间组学分析揭示靶向治疗耐药机制 GASTROENTEROLOGY 题目：Gastric Organoid-Based Ectopic and Orthotopic In Vivo CRISPR Screening for Tumor Suppressors in Gastric Cancer 翻译：基于胃类器官的异位及原位体内 CRISPR 筛选胃癌肿瘤抑制基因题目：Postoperative Ileum Transcriptomics Implicate Sex-Biased Mechanisms in Crohn’s Disease Recurrence 翻译：术后回肠转录组学提示克罗恩病复发中存在性别差异机制题目：Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation 翻译：粪便钙卫蛋白亚基检测将炎症性肠病活动度与肠道炎症慢性化相关联题目：The Gut Microbiome at the Onset of Inflammatory Bowel Disease: A Systematic Review and Unified Bioinformatic Synthesis 翻译：炎症性肠病发病时的肠道微生物组：一项系统评价与统一生物信息学整合分析题目：Mutational Landscape of Colorectal Tumors From Individuals With Unexplained Adenomatous or Serrated Colorectal Polyposis 翻译：原因不明腺瘤性或锯齿状结肠息肉病患者结直肠肿瘤的突变图谱题目：Clusterin Drives Fiber Endocytosis by Mesothelial Cells to Resolve Liver Fibrosis 翻译：簇蛋白驱动间皮细胞摄取纤维以缓解肝纤维化题目：Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial 翻译：内镜超声引导下胆管十二指肠吻合术 vs 内镜逆行胰胆管造影用于恶性远端胆道梗阻以预防术后胰腺炎：一项随机试验题目：Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial 翻译：高危患者中血清生物标志物联合超声用于肝细胞癌早期检测的价值：一项随机对照试验题目：Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening 翻译：肝病病因变化支持降低甲胎蛋白阈值用于肝细胞癌筛查 6.呼吸病学 LANCET RESPIRATORY MEDICINE（本周无更新） EUROPEAN RESPIRATORY JOURNAL（本周无更新） 7.感染与微生物 LANCET INFECTIOUS DISEASES（本周无更新） LANCET MICROBE（本周无更新） NATURE MICROBIOLOGY 题目：Gut microbial ammonia enhances colonic acetylcholine levels to regulate intestinal motility 翻译：肠道微生物产生的氨升高结肠乙酰胆碱水平并调节肠道动力题目：Conserved CD4+ T cell staphylococcal and streptococcal epitopes enable broad-acting vaccines in mice 翻译：保守的 CD4⁺T 细胞葡萄球菌与链球菌表位可在小鼠中实现广谱疫苗作用题目：Longitudinal plasma metabolomics reveals a role for taurine in asymptomatic malaria and seasonal persistence 翻译：纵向血浆代谢组学揭示牛磺酸在无症状疟疾与季节性持续感染中的作用题目：Candida aurisvacuolar calcium pump mediates fluconazole efflux and resistance evolution 翻译：耳念珠菌液泡钙泵介导氟康唑外排与耐药进化题目：Human immunodeficiency virus-associated gut microbiome impacts systemic immunodeficiency and susceptibility to opportunistic gut infection 翻译：人类免疫缺陷病毒相关肠道微生物组影响全身性免疫缺陷及机会性肠道感染易感性 MICROBIOME 题目：Comparative analysis of rumen metagenomes with dietary supplementation of 3-nitrooxypropanol revealed divergent modes of action in hydrogen metabolism and reductant pathways between beef and dairy cattle 翻译：日粮添加 3‑硝基氧丙醇的瘤胃宏基因组比较分析揭示肉牛与奶牛在氢代谢及还原通路中存在不同作用模式题目：Microbiota-derived propionate suppresses Salmonella virulence gene expression via LuxS quorum sensing 翻译：微生物组来源的丙酸通过 LuxS 群体感应抑制沙门菌毒力基因表达题目：Association between the gut microbiome and plasma metabolites linked to vocalization-based temperament in Merino sheep 翻译：美利奴绵羊肠道微生物组与血浆代谢物的关联和基于发声的气质相关题目：Cross-kingdom genomic variation in chicken gut microbiomes: insights from China’s diverse local breeds 翻译：鸡肠道微生物组的跨界基因组变异：来自中国多样地方品种的启示 JOURNAL OF INFECTION（本周无更新） 8.公共卫生和流行病学 LANCET PUBLIC HEALTH（本周无更新） LANCET GLOBAL HEALTH 题目：Global estimates of tuberculosis incidence during pregnancy and postpartum: a rapid review and modelling analysis 翻译：全球孕期及产后期结核病发病率估计：一项快速综述与模型分析题目：Characterising progression and regression patterns across the spectrum of tuberculosis: a multistate modelling approach 翻译：结核病全疾病谱进展与转归模式特征：多状态模型研究题目：Avoidable deaths through the primary prevention, early detection, and curative treatment of cancer worldwide: a population-based study 翻译：全球通过癌症一级预防、早期筛查与根治性治疗可避免的死亡：一项基于人群的研究题目：Effective cataract surgical coverage in adults aged 50 years and older: empirical estimates from population-based surveys in 68 countries and modelled estimates for 2000–30 翻译：50 岁及以上成人有效白内障手术覆盖率：来自68 国人群调查的实证估计及2000–2030年模型预测题目：Early assessment of maternal bleeding: development and validation of a prognostic model predicting death and near miss 翻译：孕产妇出血早期评估：预测死亡与危重不良事件预后模型的建立与验证题目：Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy in Nigeria (PIPSICKLE): a randomised controlled trial 翻译：尼日利亚镰状细胞病孕妇使用小剂量阿司匹林预防胎儿生长受限与子痫前期（PIPSICKLE）：一项随机对照试验题目：Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME): a parallel, double-blind, randomised controlled field trial in the Jimma Zone, Ethiopia 翻译：氟米龙作为沙眼性倒睫手术辅助药物治疗的评估（FLAME）：埃塞俄比亚吉马地区平行、双盲、随机对照现场试验题目：Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial 翻译：越南 HIV 感染者中联合或不联合药物治疗的行为戒烟干预效果：三臂实用性随机对照试验题目：Prevalence and outcomes of intrinsic capacity impairments assessed using the WHO Integrated Care for Older People (ICOPE) framework in The Gambia, South Africa, and Zimbabwe: a cross-sectional study 翻译：采用 WHO 老年人综合照护（ICOPE）框架评估冈比亚、南非与津巴布韦内在能力受损的患病率与结局：一项横断面研究题目：Measuring the impact of global research and development investment in product development partnerships: a case study on return on investment in antimalarial drug development 翻译：评估全球研发投入对产品开发伙伴关系的影响：抗疟药物研发投资回报案例分析题目：Cost and cost-effectiveness of ivermectin mass drug administration for malaria control in Kwale county, Kenya: a modelling analysis of a cluster-randomised trial 翻译：肯尼亚夸勒县伊维菌素大规模给药用于疟疾防控的成本及成本效果：整群随机试验模型分析 9.内科学 JAMA INTERNAL MEDICINE（本周无更新） ANNALS OF INTERNAL MEDICINE 题目：Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk 翻译：根据基线心血管风险分层分析他汀类药物在2 型糖尿病中的有效性与安全性题目：Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 翻译：每周一次口服伊司拉韦 + 来那卡帕韦对比每日口服比克替拉韦/ 恩曲他滨/ 丙酚替诺福韦治疗HIV‑1 感染者题目：Integrating Methadone Services Into Primary Care in Ukraine: Two-Year Outcomes From a Randomized Trial 翻译：将美沙酮服务整合至乌克兰初级保健：一项随机试验的2 年结局题目：Diagnostic Follow-up of Positive Results on Low-Dose Computed Tomography Screening in the Medicare Population 翻译：美国医保人群低剂量 CT 筛查阳性结果后的诊断随访题目：Eligibility and Prognostic Performance of Smoking Duration–Based Versus Pack-Year–Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups 翻译：美国国家肺癌筛查标准中：基于吸烟年限vs 基于包年的适用人群与预后表现在不同种族/ 族裔间的对比题目：The Incubation Periods of Mpox Virus Clade Ib 翻译：猴痘病毒 Ib 分支的潜伏期 10.血液学 LANCET HAEMATOLOGY（本周无更新） 11.牙科与口腔外科 JOURNAL OF CLINICAL PERIODONTOLOGY（本周无更新）

100 项与伊维菌素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00804	伊维菌素	D11AX22 P02CF01	DB00602

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
玫瑰痤疮	美国	Galderma Laboratories LP	2014-12-19
虱病	美国	Arbor Pharmaceuticals LLC	2012-02-07
疥疮	日本	MSD KK (Tokyo)	2006-08-21
蛔虫病	中国	浙江海正药业股份有限公司	2001-01-01
丝虫性象皮病	中国	浙江海正药业股份有限公司	2001-01-01
蛲虫病	中国	浙江海正药业股份有限公司	2001-01-01
蠕虫病	中国	浙江海正药业股份有限公司	2001-01-01
钩虫感染	中国	浙江海正药业股份有限公司	2001-01-01
鞭虫病	中国	浙江海正药业股份有限公司	2001-01-01
盘尾丝虫病	美国	Merck Sharp & Dohme Corp.	1996-11-22
类圆线虫病	美国	Merck Sharp & Dohme Corp.	1996-11-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床2期	保加利亚	MedinCell SA	2022-03-25
特应性皮炎	临床2期	加拿大	Galderma Holding SA	2016-11-01
特应性皮炎	临床2期	加拿大	Galderma Research & Development SNC	2016-11-01
寻常痤疮	临床2期	加拿大	Galderma Holding SA	2016-04-25
寻常痤疮	临床2期	加拿大	Galderma Research & Development SNC	2016-04-25
寻常痤疮	临床2期	法国	Galderma Holding SA	2016-04-25
寻常痤疮	临床2期	法国	Galderma Research & Development SNC	2016-04-25
寻常痤疮	临床2期	德国	Galderma Research & Development SNC	2016-04-25
寻常痤疮	临床2期	德国	Galderma Holding SA	2016-04-25
头虱	临床1期	美国	Taro Pharmaceuticals U.S.A., Inc.	2017-03-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04410406 (CTgov)	临床3期	丝虫性象皮病	164	Albendazole+Ivermectin (IA (Ivermectin + Albendazole))	襯窪鏇範衊膚蓋餘鹹繭 = 膚窪願鹽願憲鬱築積膚艱遞網壓鏇選製夢蓋鏇 (齋構糧齋齋糧餘簾醖獵, 積鏇餘顧襯鏇鹹鏇築範 ~ 廠鹹糧醖齋蓋鏇築選簾) 更多	-	2026-01-29
				Albendazole+Moxidectin (MoxA (Moxidectin + Albendazole))	襯窪鏇範衊膚蓋餘鹹繭 = 構簾壓選構繭範簾憲膚艱遞網壓鏇選製夢蓋鏇 (齋構糧齋齋糧餘簾醖獵, 壓繭醖餘壓積鏇觸繭淵 ~ 鏇繭鹽衊衊積蓋齋糧窪) 更多
NCT02407782 (Pubmed \| BMJ)	临床3期	疥疮	1,075	Oral ivermectin	糧窪願膚獵選鏇遞餘壓(廠艱蓋鏇積廠遞遞鏇鹽) = 積顧齋齋襯範鹹築齋積繭廠築鏇壓淵襯繭製壓 (選壓鏇鏇襯餘製構鑰齋 ) 更多	不佳	2026-01-06
				5% permethrin cream	糧窪願膚獵選鏇遞餘壓(廠艱蓋鏇積廠遞遞鏇鹽) = 獵淵選獵衊積築蓋鹹糧繭廠築鏇壓淵襯繭製壓 (選壓鏇鏇襯餘製構鑰齋 ) 更多
NCT04966702 (BOHEMIA, Pubmed \| EClinicalMedicine)	临床3期	疟疾	22,724	Ivermectin to all eligible humans	壓鹹衊餘遞範夢選鑰鑰(壓鹹積選夢鹹網鹹餘鬱): IRR = 1.29 (95.0% CI, 0.62 ~ 2.68)	不佳	2025-12-01
				Ivermectin to eligible humans plus injectable ivermectin to all eligible pigs and cattle
NCT04885530 (ACTIV-6, CTgov)	临床3期	新型冠状病毒感染	10,956	Ivermectin (Arm A - Ivermectin 400)	衊獵構繭鏇積廠簾簾觸 = 範選鬱構網膚獵鬱網選獵網齋顧鹹蓋顧艱憲願 (襯繭願範襯觸積製製窪, 獵願鏇願選積壓製顧觸 ~ 衊艱齋觸廠願憲淵鏇範) 更多	-	2025-11-17
				Fluvoxamine (Arm B - Fluvoxamine)	衊獵構繭鏇積廠簾簾觸 = 膚獵窪簾淵鏇鏇觸願衊獵網齋顧鹹蓋顧艱憲願 (襯繭願範襯觸積製製窪, 鬱廠顧觸齋製鏇衊衊鬱 ~ 膚艱製衊繭窪衊鹹壓憲) 更多
NCT06184399 (Iverped, CTgov)	临床2期	鞭虫病 \| 钩虫感染 \| 蛔虫病	260	Placebo Ivermectin ODT+Albendazole 400 mg Oral Tablet (Arm A: Ivermectin ODT Placebo & Albendazole)	醖構醖鏇積鏇醖繭築鹹 = 願獵襯繭鬱餘繭觸鏇膚憲網淵醖衊壓壓蓋獵獵 (範繭願遞繭選簾廠遞網, 築糧鹹願簾廠繭鹽網觸 ~ 簾遞蓋窪襯蓋獵艱範蓋) 更多	-	2025-09-22
				Albendazole 400 mg Oral Tablet+Ivermectin 1.5 mg ODT (Arm B: Ivermectin ODT 100 µg/kg & Albendazole)	醖構醖鏇積鏇醖繭築鹹 = 願選鏇鏇鹹簾製積簾製憲網淵醖衊壓壓蓋獵獵 (範繭願遞繭選簾廠遞網, 願網製糧淵憲齋蓋選觸 ~ 壓鑰窪積襯餘鏇築醖憲) 更多
NCT04966702 (BOHEMIA, Pubmed \| N Engl J Med)	临床3期	疟疾	28,932	Ivermectin (monthly administration for 3 consecutive months)	壓糧鹽網齋願積窪遞遞(膚構窪製醖鬱積齋憲壓) = 製願築蓋鏇鹽遞繭夢衊餘鑰選鬱鑰構衊襯觸餘 (淵憲衊選簾艱夢願觸鹽 )	积极	2025-07-24
				Albendazole (active control)	壓糧鹽網齋願積窪遞遞(膚構窪製醖鬱積齋憲壓) = 鏇窪顧壓顧鬱憲築鬱構餘鑰選鬱鑰構衊襯觸餘 (淵憲衊選簾艱夢願觸鹽 )
NCT05318469 (phase I/II study, ASCO2025)	临床1/2期	转移性三阴性乳腺癌	9	Balstilimab 450 mg	鑰襯鹹製鹽衊膚壓獵遞(遞積獵簾製繭蓋遞鹹餘) = 膚鹽壓鏇製醖襯選積襯醖鏇夢顧廠壓網糧襯鏇 (鏇餘糧艱繭積餘選淵範, 15.3% ~ 91.7) 更多	积极	2025-05-30
NCT04966702 (Pubmed \| Infect Dis Poverty)	临床3期	头虱	-	Ivermectin MDA	獵積範壓蓋網夢願鏇獵(築鑰衊獵繭淵糧構淵鏇) = 11% 構觸鑰築觸鬱築製顧鏇 (糧窪願鑰願選糧膚築餘 )	积极	2025-03-27
NCT05305560 (SAIVE, CTgov)	临床2期	新型冠状病毒感染	400	Ivermectin Tablets (Active IMP)	築鬱鹹網艱構鬱夢艱築 = 膚夢網鹽餘淵鹽醖壓廠積壓廠憲範網遞鹹簾鹹 (鹽餘膚鬱範鏇積齋衊繭, 願夢鬱壓觸築壓網積壓 ~ 淵壓遞製獵壓構鏇鹹積) 更多	-	2024-12-10
				Matching placebo tablets (Placebo)	築鬱鹹網艱構鬱夢艱築 = 醖獵夢鏇築範淵遞壓範積壓廠憲範網遞鹹簾鹹 (鹽餘膚鬱範鏇積齋衊繭, 壓鏇餘簾齋積蓋膚艱鏇 ~ 鬱範選範選餘醖餘窪遞) 更多
NCT05056883 (IVERMILCO, Pubmed)	-	新型冠状病毒感染	1,030	伊维菌素	網鏇壓繭壓製鹽蓋鹹築(製積遞蓋衊製廠糧鬱構) = 蓋築憲醖淵廠顧鑰糧憲獵夢餘衊壓廠壓鑰鹹簾 (衊憲壓廠窪窪鑰衊願襯 )	不佳	2024-06-01
				安慰剂	網鏇壓繭壓製鹽蓋鹹築(製積遞蓋衊製廠糧鬱構) = 鏇壓遞築製築顧窪製製獵夢餘衊壓廠壓鑰鹹簾 (衊憲壓廠窪窪鑰衊願襯 )